Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
Recruiting
Observational Study
Insulinoma; Pancreas
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 15 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 20 (estimated)
- Sponsor
- Sahlgrenska University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies. In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Insulinoma verified by pathology (often from EUS-FNB-sampling)
Exclusion Criteria:
* Patients unwilling to participate
* Patients unable to understand and obtain written informed conscent
* Severe comorbidity
Contacts
Riadh Sadik, Associate Professor
+46 31 3421000
CONTACT